AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32829304
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept injection (IAI) every 12 weeks (q12wk)
Trial: 32997826
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pain on maximum jaw opening and pain on palpation using DC/TMD
Trial: 34843183
Drug: Spironolactone (12.5-25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5-25-50 mg/day)
Trial: 33904027
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 50 mg/day
Trial: 32059924
Drug: Concurrent Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
Trial: 33345885
Drug: 17-hydroxyprogesterone caproate
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-hydroxyprogesterone caproate adherence (greater than 80% of intended injections)
Trial: 32891604
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (HbA1c under 6.2%, blood pressure under 120/75 mmHg, low-density lipoprotein cholesterol under 80 mg/dL)
Trial: 32891604
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (HbA1c under 6.9%, blood pressure under 130/80 mmHg, low-density lipoprotein cholesterol under 120 mg/dL)
Trial: 33992287
Drug: Neurodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamic Therapy (NDT)
Trial: 32534221
Drug: Zoledronate 5
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate 5 mg infusion
Trial: 36052897
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of amiodarone diluted in 50 mL of 5% dextrose over 10 min
Trial: 36052897
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL of 5% dextrose over 10 min
Trial: 36052897
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of amiodarone
Trial: 36052897
Drug: 50 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mL of 5% dextrose
Trial: 34589083
Drug: BLXA4 oral
RxNorm normalized name: BLXA4
DrugBank: BLXA4 (DB12133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLXA4 oral rinse
Trial: 34700571
Drug: 22-gene genomic
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 22-gene genomic classifier (GC) scores in patients receiving short-term or long-term androgen-deprivation therapy (ADT).
Trial: 35072987
Drug: Spinach intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinach intake (both treatments)
Trial: 32295504
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue-type plasminogen activator
Trial: 36215947
Drug: Vaccine +
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine + OPT-821
Trial: 35040959
Drug: JNJ‐64530440 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐64530440 750 mg once daily
Trial: 35040959
Drug: JNJ‐64530440 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐64530440 750 mg twice daily
Trial: 34224930
Drug: GA-PCA (general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GA-PCA (general anaesthesia with morphine patient-controlled analgesia)
Trial: 36084645
Drug: Intensive lifestyle
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive lifestyle therapy (energy restriction and exercise)
Trial: 32669521
Drug: Verbascox® (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbascox® (800 mg/day) for 2 weeks
Trial: 32669521
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg/day) for 2 weeks
Trial: 33588150
Drug: Gem/afatinib (Gem:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gem/afatinib (Gem: 1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks; Afatinib: 40 mg orally once daily)
Trial: 33588150
Drug: Gem alone
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gem alone (1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks)
Trial: 32949542
Drug: Galcanezumab 120
RxNorm normalized name: Galcanezumab 120 mg/mL solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for 3 months
Trial: 34372818
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (IV + topical-TXA)
Trial: 33422006
Drug: Cumulative bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cumulative bevacizumab doses (various metrics including cumulative dose, quantiles of cumulative dose, standardized cumulative dose, Theoretical Blood Concentration (TBC), and Weighted Cumulative Exposure (WCE))
Trial: 33422006
Drug: Cumulative bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cumulative bevacizumab doses
Trial: 33226845
Drug: KOOS Activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KOOS Activities of Daily Living (ADL)
Trial: 32912157
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 mg TID for 3 months followed by 50 mg TID for 3 months; n=30)
Trial: 33822654
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy services for 30 min twice weekly
Trial: 33822654
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy services for 15 min 4 times weekly
Trial: 34320865
Drug: PECS-1 block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECS-1 block with 0.4 mL kg−1 0.25% bupivacaine
Trial: 34320865
Drug: Infiltration anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration anesthesia with 0.4 mL kg−1 0.25% bupivacaine
Trial: 34571187
Drug: Erector spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector spinae plane block (ESPB) with 30 mL of 0.375% ropivacaine
Trial: 34571187
Drug: Sham block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham block with 30 mL of 0.9% saline
Trial: 32664105
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose group A (120 kVp, 150 mAs)
Trial: 32664105
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group B (120 kVp, 50 mAs)
Trial: 32664105
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group C (100 kVp, 50 mAs)
Trial: 32664105
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group D (100 kVp, 30 mAs)
Trial: 34759247
Drug: Immediate surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate surgery after chemotherapy (arm A)
Trial: 35081010
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg twice daily for 48 hours)
Trial: 33640257
Drug: Lavender aromatherapy
RxNorm normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lavender aromatherapy (inhalation for five minutes, three times a week)
Trial: 35492241
Drug: LEAP2 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LEAP2 infusion
Trial: 35492241
Drug: LEAP2 dosing
RxNorm normalized name: ALCOHOL 17.57 g in 30 mL TOPICAL LIQUID [Leap Frog Fresh HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEAP2 dosing in wild-type mice
Trial: 33152443
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MT)
Trial: 33926724
Drug: Fault detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fault detection performance index based on stochastic robustness/sensitivity ratio; specific dosage and duration not mentioned.
Trial: 33926724
Drug: Fault detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fault detection threshold setting algorithms using Randomized Algorithms; specific dosage and duration not mentioned.
Trial: 32029684
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (PCV13 and DTaP at visit 1, IIV4 at visit 2)
Trial: 32243660
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) + Game therapy (GT)
Trial: 35325969
Drug: Hypochloric acid
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypochloric acid (100 μg/mL)
Trial: 35325969
Drug: Povidone iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone iodine (50 mg/mL)
Trial: 32459885
Drug: Opicapone 25
RxNorm normalized name: opicapone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 25 mg tablet
Trial: 32459885
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg tablet
Trial: 32459885
Drug: Opicapone 25
RxNorm normalized name: opicapone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 25 mg capsule
Trial: 32459885
Drug: Opicapone 50
RxNorm normalized name: opicapone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opicapone 50 mg capsule
Trial: 34689288
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (oral prednisolone 60 mg daily with gradual taper-off to 35 mg/day and cyclosporine 3 mg/kg/day)
Trial: 34689288
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy (methylprednisolone 1000 mg for 3 days followed by oral prednisolone)
Trial: 32598793
Drug: Enisamium iodide
RxNorm normalized name: enisamium iodide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enisamium iodide with symptomatic therapy
Trial: 32598793
Drug: Symptomatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic therapy only (Control)
Trial: 35110688
Drug: THC (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (7.5, 15 mg)
Trial: 33051039
Drug: Music Therapy-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy-Based Stress Reduction (MTSR)
Trial: 33377716
Drug: Priligy (dapoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priligy (dapoxetine hydrochloride) 30 mg 1-3 hours before sexual activity combined with behavioral therapy and psychological counseling (30 minutes, once a month for two times)
Trial: 33377716
Drug: Priligy (dapoxetine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priligy (dapoxetine hydrochloride) 30 mg 1-3 hours before sexual activity
Trial: 36412415
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of single agent, 3 weekly injection paclitaxel 175 mg/m2 as maintenance therapy
Trial: 33919991
Drug: L-carnitine tartrate
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine tartrate supplementation
Trial: 33400778
Drug: Adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted trivalent influenza vaccine (aTIV)
Trial: 36215334
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) + snail control
Trial: 36215334
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) alone
Trial: 36215334
Drug: Mass drug
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass drug administration (MDA) + behavioral change interventions
Trial: 32840412
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg daily for seven days)
Trial: 32840412
Drug: Roxithromycin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (300 mg daily for seven days)
Trial: 32508327
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg BID
Trial: 32502243
Drug: High phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High phosphorus intake (≥ 1375 mg/d)
Trial: 32502243
Drug: Low phosphorus
RxNorm normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low phosphorus intake (< 1100 mg/d)
Trial: 34892575
Drug: Spatially Distributed
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatially Distributed Sequential Stimulation (SDSS)
Trial: 33693678
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of any majority DRM with <2 active drugs
Trial: 36155982
Drug: Ultra-low-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose CT scans
Trial: 36155982
Drug: Standard-dose CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CT scans
Trial: 33820636
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (4°C)
Trial: 32413673
Drug: CAG repeat
RxNorm normalized name: an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAG repeat polymorphism of the androgen receptor gene
Trial: 35969885
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen 0.45 mg/d
Trial: 35969885
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol 50 mg/d (patch replaced weekly)
Trial: 33629110
Drug: Anifrolumab 1000
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 1000 mg every 4 weeks
Trial: 32952837
Drug: Good oral
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Good oral hygiene status
Trial: 32594453
Drug: Liraglutide (L)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (L) therapy at a final dose of 3.0 mg/day
Trial: 32594453
Drug: Liraglutide (L)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (L) therapy
Trial: 34932102
Drug: All RSVpreF
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All RSVpreF formulations
Trial: 34962176
Drug: Film therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film therapy analysis (12 sessions, one session per week)
Trial: 34684442
Drug: Monitored therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitored therapy (n = 54; with an option of dose modification)
Trial: 34684442
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n = 55; 500 IU vitamin D standard therapy)
Trial: 35381950
Drug: Thyroid-stimulating hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid-stimulating hormone (TSH)
Trial: 34294114
Drug: Intravenous nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nimodipine 1–2 mg/h from the day before surgery until the fifth postoperative day and standard of care
Trial: 39217559
Drug: Semaglutide 2.4
RxNorm normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 2.4 mg
Trial: 32074268
Drug: Antibiotics (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (intravenous ertapenem 1 g once daily for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Trial: 32074268
Drug: Antibiotics (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (with subsequent appendectomy)
Trial: 32074268
Drug: Successful antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful antibiotic therapy
Trial: 32417345
Drug: 36 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 36 Gy in 6 fractions, twice a week (arm 1)
Trial: 616651858
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a injected subcutaneously three times weekly (IFN beta-1a SC tiw)
Trial: 616651858
Drug: Interferon beta-1a
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1a injected intramuscularly once weekly (IFN beta-1a IM qw)
Trial: 32506992
Drug: EG1 -
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: EG1 - Treatment group designed to change sexual scripts for consensual sex
Trial: 32506992
Drug: EG2 -
RxNorm normalized name: Ethinyl Estradiol and Gestodene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG2 - Treatment group designed to promote sexual self-esteem and challenge perceived realism of pornography
Trial: 32506992
Drug: CG -
RxNorm normalized name: HCG - Human chorionic gonadotropin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG - Non-treatment control group
Trial: 32000816
Drug: Subperiosteal cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subperiosteal cocktail injection
Trial: 34182998
Drug: BUD/FORM DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FORM DPI 400/12 μg
Trial: 34724323
Drug: Localized microinjections
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized microinjections of tranexamic acid (4 mg/ml) plus Q-switched 1064 laser every 2 weeks
Trial: 34724323
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid 250 mg three times a day plus Q-switched 1064 laser every 2 weeks
Trial: 32910831
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 at 1 mL/kg/h (group 1)
Trial: 32910831
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 at 2 mL/kg/h (group 2)
Trial: 34958142
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day montelukast (Group 2)
Trial: 34958142
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day montelukast (Group 3)
Trial: 34958142
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Group 1)
Trial: 35131378
Drug: Collaborative care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collaborative care (medication therapy management and telephonic follow‐up with visits to family physicians, nurses, and dietitians)
Trial: 34656226
Drug: Liposomal irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal irinotecan (70 mg/m2 for 90 min) plus leucovorin (400 mg/m2 for 30 min) and fluorouracil (2400 mg/m2 for 46 h) every 2 weeks
Trial: 36282079
Drug: CSL112 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL112 (2 g and 6 g)
Trial: 35268057
Drug: Ca+vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca+vitamin D supplements (S)
Trial: 35268057
Drug: Control/placebo pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/placebo pills (C)